Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

Chest. 2004 Sep;126(3 Suppl):234S-264S. doi: 10.1378/chest.126.3_suppl.234S.

Abstract

This article discusses platelet active drugs as part of the Seventh American College of Chest Physicians Conference on Antithrombotic and Thrombolytic Therapy: Evidence-Based Guidelines. New data on antiplatelet agents include the following: (1) the role of aspirin in primary prevention has been the subject of recommendations based on the assessment of cardiovascular risk; (2) an increasing number of reports suggest a substantial interindividual variability in the response to antiplatelet agents, and various phenomena of "resistance" to the antiplatelet effects of aspirin and clopidogrel; (3) the benefit/risk profile of currently available glycoprotein IIb/IIIa antagonists is substantially uncertain for patients with acute coronary syndromes who are not routinely scheduled for early revascularization; (4) there is an expanding role for the combination of aspirin and clopidogrel in the long-term management of high-risk patients; and (5) the cardiovascular effects of selective and nonselective cyclooxygenase-2 inhibitors have been the subject of increasing attention.

Publication types

  • Comparative Study

MeSH terms

  • Administration, Oral
  • Aspirin / administration & dosage*
  • Aspirin / adverse effects
  • Aspirin / pharmacokinetics
  • Clopidogrel
  • Coronary Thrombosis / blood
  • Coronary Thrombosis / drug therapy*
  • Evidence-Based Medicine
  • Humans
  • Myocardial Revascularization
  • Platelet Aggregation Inhibitors / administration & dosage*
  • Platelet Aggregation Inhibitors / adverse effects
  • Platelet Aggregation Inhibitors / pharmacokinetics
  • Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors*
  • Randomized Controlled Trials as Topic
  • Risk Factors
  • Thromboembolism / blood
  • Thromboembolism / drug therapy*
  • Ticlopidine / administration & dosage*
  • Ticlopidine / adverse effects
  • Ticlopidine / analogs & derivatives*
  • Ticlopidine / pharmacokinetics
  • Treatment Outcome

Substances

  • Platelet Aggregation Inhibitors
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Clopidogrel
  • Ticlopidine
  • Aspirin